Second quarter
- Net sales amounted to kSEK 5 (0)
- Profit before tax amounted to kSEK - 3 796 (-2 557)
-
Earnings per share amounted to
SEK -0,44 (-0,61) - Cash flow from operating activities totaled to kSEK -850 (-1 745)
- The order book amounted to kSEK 1 122 (596) at the end of the quarter
Period 1 January - 30 June
- Net sales amounted to kSEK 30 (90)
- Profit before tax amounted to kSEK -6 581 (-6 021)
-
Earnings per share amounted to
SEK -0,81 (-1,59) - Cash flow from operating activities totaled to kSEK -6 414 (-5 865)
- The order book amounted to kSEK 1 122 (596) at the end of the period
Important events during the quarter
- Eva Ståhl Wernersson assumed the role of QM /RA Director
Vetiqure AB recruited a product specialistElin Wallin and ChemoTech recruited COOUrban Wid én- ChemoTech signed a loan in April for kSEK 2 000 with a loan promise of kSEK 10 000
- ChemoTech received CE marking for its product IQwave
- ChemoTech investigated the possibility of conducting studies in the US for treatment of pancreatic cancer
Important events after the quarter
Vetiqure AB signed an agreement with Diversified Consultant Group Int. LLC in the US to implement a feasibility study for its Go-To-Market strategy when vetIQure launches in the US
SUMMARY
The most important event of the second quarter was obtaining the CE certificate for our innovation IQwave 3.0 CE, for the treatment of various cancer indications in human medicine. Although the CE marking primarily gives us permission to start marketing and sales within
Within Animal Care, the product vetIQure is already on the market in
Sales were kSEK 5 during the period and the result was kSEK -3 796 compared to kSEK -2 557 for the same period last year. We have still have several machines in our order book but due to the continuation of strict restrictions, these deliveries has been further postponed. Cash flow was for the period, kSEK -2 298, compared to kSEK 5 864 same period last year. The Company received new credit from external financiers during the quarter. The loan promise is kSEK 10 000 and during the quarter the company lifted kSEK 2 000 of these.
The CE-marking has made it possible for us to now open up markets where we already have established distributor agreements with experienced business developers in oncology and we will invest in these markets in the upcoming year. We will also establish contacts to generate more clinical data for countries with national treatment regimes that require this. The product development of new electrodes to treat deep-seated tumours is still ongoing and our goal is still to have a CE marked treatment kit ready by the end of this year.
An important part of the company's product development is also to continue to strengthen the patent portfolio. We received a pre-notice for a granted EU patent for the treatment of skeletal cancer and cancer of the spine. This success can also have a positive impact on our Horizon application.
As part of the strategic work, we will continue with the development of our international organization. This is to promote both sales and the capacity to start and run clinical studies. This development will be absolutely crucial as we now expand to new indications and include
The full version of the Interim Q2 report was published in Swedish
For more information, please contact:
Phone: +46 (0)10-218 93 00
info@chemotech.se
Certified Adviser:
ChemoTech is a Swedish medical technology company based in
https://news.cision.com/chemotech/r/scandinavian-chemotech-ab--publ--interim-report-q1-january---june-2021---executive-summary-of-the-se,c3402571
https://mb.cision.com/Main/14967/3402571/1458470.pdf
https://news.cision.com/chemotech/i/executive-summary,c2947171
(c) 2021 Cision. All rights reserved., source